User menu

Effect of Acute and Long-term Vagus Nerve Stimulation in Fully Kindled Rats

Bibliographic reference Raedt, R. ; Waterschoot, L. ; Wyckhuys, T. ; De Herdt, V. ; El Tahry, R. ; et. al. Effect of Acute and Long-term Vagus Nerve Stimulation in Fully Kindled Rats.8th European Congress on Epileptology (Berlin(Germany), Sep 21-25, 2008). In: Epilepsia, Vol. 50, p. 93 (2009)
Permanent URL http://hdl.handle.net/2078.1/58971
  1. Adab, J Neurol Neurosurg Psychiatry, 70, 15 (2001)
  2. Anhut, Epilepsia, 35, 795 (1994)
  3. Appleton, Epilepsia, 40, 1147 (1999)
  4. Arroyo, Epilepsia, 45, 20 (2004)
  5. Asconapé, Epilepsia, 34, 177 (1993)
  6. Beghi, Epilepsia, 29, 236 (1988)
  7. Ben-Menachem, Epilepsia, 41, 1276 (2000)
  8. Ben-Menachem, Epilepsia, 37, 539 (1996)
  9. Ben-Menachem, Epilepsia, 48, 1308 (2007)
  10. Besag, Seizure, 6, 51 (1997)
  11. Beydoun A., Sachdeo R. C., Rosenfeld W. E., Krauss G. L., Sessler N., Mesenbrink P., Kramer L., D'Souza J., Oxcarbazepine monotherapy for partial-onset seizures: A multicenter, double-blind, clinical trial, 10.1212/wnl.54.12.2245
  12. Beydoun A., Uthman B. M., Kugler A. R., Greiner M. J., Knapp L. E., Garofalo E. A., , Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy, 10.1212/01.wnl.0000150932.48688.be
  13. Bialer, Epilepsy Res, 25, 299 (1996)
  14. Bialer, Epilepsy Res, 34, 1 (1999)
  15. Bialer, Epilepsy Res, 43, 11 (2001)
  16. Bialer, Epilepsy Res, 51, 31 (2002)
  17. Bialer, Epilepsy Res, 61, 1 (2004)
  18. Bialer, Epilepsy Res, 73, 1 (2007)
  19. Bill, Epilepsy Res, 27, 195 (1997)
  20. Binnie, Epilepsia, 27, 248 (1986)
  21. Binnie, Epilepsy Res, 1, 202 (1987)
  22. Bird, Br J Psychiatry, 112, 737 (1966)
  23. Biton V., Montouris G. D., Ritter F., Riviello J. J., Reife R., Lim P., Pledger G., A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures, 10.1212/wnl.52.7.1330
  24. Blom, Lancet, 1, 829 (1962)
  25. Bonduelle, Rev Neurol, 110, 209 (1964)
  26. Brodie, Lancet, 345, 476 (1995)
  27. Brodie, Epilepsy Res, 37, 81 (1999)
  28. Browne, Epilepsia, 14, 277 (1973)
  29. Buchthal, Epilepsia, 1, 373 (1960)
  30. Buchthal, Psychiatry Neurol Neurochir, 74, 117 (1971)
  31. BUCHTHAL F., SVENSMARK O., SCHILLER P. J., Clinical and Electroencephalographic Correlations with Serum Levels of Diphenylhydantoin, 10.1001/archneur.1960.03840120030004
  32. Buchthal F., Svensmark O., Simonsen H., Relation of EEG and Seizures to Phenobarbital in Serum, 10.1001/archneur.1968.00480060037004
  33. Canadian Study Group for Childhood Epilepsy, Epilepsia, 39, 952 (1998)
  34. Carraz, Annales médico-psychologiques, 577 (1964)
  35. CEREGHINO J. J., BROCK J. T., VAN METER J. C., PENRY J. K., SMITH L. D., WHITE B. G., Carbamazepine for epilepsy: A controlled prospective evaluation, 10.1212/wnl.24.5.401
  36. Cereghino, Neurology, 55, 236 (2000)
  37. Chadwick, Lancet, 354, 13 (1999)
  38. Chadwick D. W., Anhut H., Greiner M. J., Alexander J., Murray G. H., Garofalo E. A., Pierce M. W., , A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures, 10.1212/wnl.51.5.1282
  39. Chapman, Epilepsia, 19, 293 (1978)
  40. Christe, Epilepsy Res, 26, 451 (1997)
  41. Chung, Nature, 428, 486 (2004)
  42. Coatsworth, Studies on the clinical efficacy of marketed antiepileptic drugs (1971)
  43. Cockerell, Epilepsia, 38, 31 (1997)
  44. Cohen AF, Ashby L., Crowley D., Land G., Peck AW, Miller AA, Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam., 10.1111/j.1365-2125.1985.tb05120.x
  45. Commission for the Control of Epilepsy and Its Consequences, Plan for nationwide action in epilepsy (1978)
  46. Coulter, Lancet, 14, 1310 (1980)
  47. Dalens, Pediatrics, 97, 332 (1980)
  48. Dam, J Neurol Neurosurg Psychiatry, 52, 472 (1989)
  49. Dreifuss F. E., Santilli N., Langer D. H., Sweeney K. P., Moline K. A., Menander K. B., Valproic acid hepatic fatalities: A retrospective review, 10.1212/wnl.37.3.379
  50. Duchowny M., Pellock J. M., Graf W. D., Billard C., Gilman J., Casale E., Womble G., Risner M., Manasco P., A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children, 10.1212/wnl.53.8.1724
  51. Eke T, Talbot J F, Lawden M C, Severe persistent visual field constriction associated with vigabatrin, 10.1136/bmj.314.7075.180
  52. Elger, Epilepsia, 46, 1926 (2005)
  53. Ellison, Advances in epileptology: the XVIIth Epilepsy International Congress, 435 (1989)
  54. Elterman R. D., Glauser T. A., Wyllie E., Reife R., Wu S.-C., Pledger G., A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children, 10.1212/wnl.52.7.1338
  55. Eriksson, Epilepsia, 39, 495 (1998)
  56. Faught E., Wilder B. J., Ramsay R. E., Reife R. A., Kramer L. D., Pledger G. W., Karim R. M., Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages, 10.1212/wnl.46.6.1684
  57. Faught E., Ayala R., Montouris G. G., Leppik I. E., Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures, 10.1212/wnl.57.10.1774
  58. Feely, Lancet, 2, 71 (1982)
  59. Gastaut, Epilepsia, 20, 437 (1979)
  60. Gastaut, Epilepsia, 6, 167 (1965)
  61. Gastaut, Epilepsia, 12, 197 (1971)
  62. Gilliam F.G., Veloso F., Bomhof M.A.M., Gazda S.K., Biton V., Ter Bruggen J.P., Neto W., Bailey C., Pledger G., Wu S.-C., A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy, 10.1212/01.wnl.0000048200.12663.bc
  63. Glauser T. A., Nigro M., Sachdeo R., Pasteris L. A., Weinstein S., Abou-Khalil B., Frank L. M., Grinspan A., Guarino T., Bettis D., Kerrigan J., Geoffroy G., Mandelbaum D., Jacobs T., Mesenbrink P., Kramer L., D'Souza J., Adjunctive therapy with oxcarbazepine in children with partial seizures, 10.1212/wnl.54.12.2237
  64. Glauser, Epilepsia, 47, 1094 (2006)
  65. Gomez, J Pediatr, 98, 508 (1981)
  66. Gram, Acta Neurol Scand, 68, 34 (1983)
  67. Gram, Ann Neurol, 17, 262 (1985)
  68. Green, Epilepsia, 15, 329 (1974)
  69. Guelen P. J. M., van der Kleijn E., Woudstra U., Statistical Analysis of Pharmacokinetic Parameters in Epileptic Patients Chronically Treated with Anti-Epileptic Drugs, Clinical Pharmacology of Anti-Epileptic Drugs (1975) ISBN:9783642859236 p.2-10, 10.1007/978-3-642-85921-2_1
  70. Guerreiro, Epilepsy Res, 27, 205 (1997)
  71. Haerer AF , Buchanan RA , Wiygul FM (1970) Ethosuximide blood levels in epileptics.
  72. Hansen Svend Erik, Quantitative Determination of Etosuximide (Zarontin ®, α-methyl, - α-ethylsuccinimide) in Serum, 10.1111/j.1600-0773.1964.tb01747.x
  73. Harvey, Br Med J, 2, 603 (1975)
  74. Heathfield, Br Med J, 2, 565 (1961)
  75. Helferich, Liebigs Ann Chem, 441, 427 (1960)
  76. Heller, J Neurol Neurosurg Psychiatry, 58, 44 (1995)
  77. Hensen, Epilepsia, 9, 17 (1968)
  78. Isojärvi, N Engl J Med, 329, 1383 (1993)
  79. Jawad, Epilepsia, 30, 356 (1989)
  80. Jongmans, Epilepsia, 5, 74 (1964)
  81. Kälviäinen Reetta, Vigabatrin vs Carbamazepine Monotherapy in Patients With Newly Diagnosed Epilepsy : A Randomized, Controlled Study, 10.1001/archneur.1995.00540340081016
  82. Kälviäinen, Epilepsy Res, 25, 291 (1996)
  83. Kälviäinen, Epilepsy Res, 30, 31 (1998)
  84. Korean Topiramate Study Group, Epilepsia, 40, 1767 (1999)
  85. Krall, Epilepsia, 19, 393 (1978)
  86. Kumar, Pharm Exec (2003)
  87. Kupferberg, Epilepsia, 30, S51 (1989)
  88. Kutt H., Penry J. K., Usefulness of Blood Levels of Antiepileptic Drugs, 10.1001/archneur.1974.00490410031001
  89. Lamb, Br J Pharmacol, 85, 235 (1985)
  90. Lennox, Epilepsy and related disorders (1960)
  91. Leppik I. E., Dreifuss F. E., Pledger G. W., Graves N. M., Santilli N., Drury I., Tsay J. Y., Jacobs M. P., Bertram E., Cereghino J. J., Cooper G., Sahlroot J. T., Sheridan P., Ashworth M., Lee S. I., Sierzant T. L., Felbamate for partial seizures: Results of a controlled clinical trial, 10.1212/wnl.41.11.1785
  92. Lippert, Eur J Biochem, 74, 441 (1977)
  93. Livingston, J Am Med Assoc, 180, 822 (1962)
  94. Livingston, J Am Med Assoc, 194, 227 (1965)
  95. Livingston, J Am Med Assoc, 204, 731 (1968)
  96. Loiseau, Epilepsia, 27, 115 (1986)
  97. Loiseau, Epilepsy Res, 7, 136 (1990)
  98. Lorgé, Psychiatry Neurol, 147, 360 (1964)
  99. Luciano, Ann Neurol, 62, 375 (2007)
  100. MacDonald, Ann Neurol, 48, 833 (2000)
  101. Mann, Bull Los Angeles Neurol Soc, 27, 173 (1962)
  102. Marjerrison, Dis Nerv Syst, 1968, 133 (1968)
  103. Marson, Epilepsia, 38, 859 (1997)
  104. Marson, Neurology, 67, 1872 (2006)
  105. Marson, Lancet, 369, 1016 (2007)
  106. Marson, Lancet, 369, 1000 (2007)
  107. Matsuo F., Bergen D., Faught E., Messenheimer J. A., Dren A. T., Rudd G. D., Lineberry C. G., , Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures, 10.1212/wnl.43.11.2284
  108. Mauguière, Epilepsia, 38, 301 (1997)
  109. Mbuba, Epilepsia, 49, 1491 (2008)
  110. McLean, J Pharmacol Exp Ther, 238, 727 (1986)
  111. Meinardi, Psychiatry Neurol Neurochir, 74, 141 (1971)
  112. Meldrum, Psychopharmacology, 59, 47 (1978)
  113. Messenheimer, Epilepsia, 35, 113 (1994)
  114. Meunier, Thérapie, 435 (1963)
  115. Miller, J Am Chem Soc, 75, 373 (1953)
  116. Miller, J Am Chem Soc, 73, 5608 (1951)
  117. Motte, N Engl J Med, 337, 1807 (1998)
  118. Muller, Z Kinderheilkd, 88, 548 (1963)
  119. Neligan A , Shorvon SD (2009). The modern history of status epilepticus and its treatment Epilepsia (in press).
  120. Nieto-Barrera, Epilepsy Res, 46, 145 (2001)
  121. Pedley, Epilepsia, 20, 409 (1979)
  122. Penry, Epilepsia, 14, 451 (1973)
  123. PenryJK, RapportRLII. (Eds) (1973) Epilepsy bibliography, 1900-1950. US Government Printing Office, Washington DC.
  124. Penry, Antiepileptic drugs, 431 (1972)
  125. Poiré, Rév Neurolog, 108, 112 (1963)
  126. Pryse-Phillips, Epilepsia, 11, 263 (1970)
  127. Rajotte, Union Med Can, 96, 1200 (1967)
  128. Remy, Boll Lega It Epil, 5455, 241 (1986)
  129. Reunanen, Epilepsy Res, 23, 149 (1996)
  130. Reynolds, Epilepsia, 22, 1 (1981)
  131. Reynolds, QJM, 35, 521 (1966)
  132. Reynolds, Lancet, 1, 923 (1976)
  133. Richens, Epilepsy Res, 21, 37 (1995)
  134. Rimmer, Lancet, 1, 189 (1984)
  135. Ring, Recent advances in epilepsy, 5, 177 (1992)
  136. Robert, Lancet, 2, 937 (1982)
  137. da Rocha, Neuroradiology, 48, 731 (2006)
  138. Rodin, Epilepsia, 15, 547 (1974)
  139. Rosenstein, Dis Nerv Syst, 21, 57 (1960)
  140. Rzany, Lancet, 354, 1033 (1999)
  141. Sachdeo Rajesh C., Tiagabine Therapy for Complex Partial Seizures : A Dose-Frequency Study, 10.1001/archneur.1997.00550170069016
  142. Sachdeo R. C., Glauser T. A., Ritter F., Reife R., Lim P., Pledger G., A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome, 10.1212/wnl.52.9.1882
  143. Sachdeo R., Beydoun A., Schachter S., Vazquez B., Schaul N., Mesenbrink P., Kramer L., D'Souza J., Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures, 10.1212/wnl.57.5.864
  144. Sander, Epilepsy Res, 6, 221 (1990)
  145. Sander, J Neurol Neurosurg Psychiatry, 54, 435 (1991)
  146. Schachter S. C., Vazquez B., Fisher R. S., Laxer K. D., Montouris G. D., Combs-Cantrell D. T., Faught E., Willmore L. J., Morris G. L., Ojemann L., Bennett D., Mesenbrink P., Souza J. D', Kramer L., Oxcarbazepine: Double-blind, randomized, placebo-control, monotherapy trial for partial seizures, 10.1212/wnl.52.4.732
  147. Schapel, J Neurol Neurosurg Psychiatry, 56, 448 (1993)
  148. Schauf, J Pharmacol Exp Ther, 189, 538 (1974)
  149. Schechter, Eur J Pharmacol, 45, 319 (1977)
  150. Schindler, Helv Chim Acta, 37, 472 (1954)
  151. Schmidt, Epilepsy Res, 15, 67 (1993)
  152. Sharief, Epilepsy Res, 25, 217 (1996)
  153. Sherwin A. L., Robb J. P., Lechter M., Improved Control of Epilepsy by Monitoring Plasma Ethosuximide, 10.1001/archneur.1973.00490210058007
  154. Shorvon, J Neurol Neurosurg Psychiatry, 47, 1157 (1984)
  155. Shorvon, Antiepileptic drugs, 821 (1989)
  156. Shorvon, Antiepileptic drugs, 763 (1995)
  157. Shorvon, Lancet, 358, 1885 (2001)
  158. Shorvon, Epilepsia, 47, 1091 (2006)
  159. Shorvon, The treatment of epilepsy (2009)
  160. Shorvon, Epilepsia, 29, 36 (1988)
  161. Shorvon, Br Med J, i, 1635 (1977)
  162. Shorvon, Br Med J, i, 1023 (1979)
  163. Shorvon, Br Med J, i, 474 (1978)
  164. Shorvon, Advances in Epileptology: The XIIth Epilepsy International Symposium, 123 (1981)
  165. Shorvon, Epilepsia, 41, 1179 (2000)
  166. The Treatment of Epilepsy, ISBN:9781444316667, 10.1002/9781444316667
  167. Shorvon, International League Against Epilepsy (ILAE) 1909-2009: a centenary history (2009)
  168. Sillanpaa, Brain, 129, 617 (2006)
  169. de Silva, Lancet, 347, 709 (1996)
  170. Silvenius, Epilepsia, 32, 539 (1991)
  171. Simon, Epilepsia, 16, 549 (1975)
  172. Simonsen, Ugeskr Laeger, 137, 2392 (1975)
  173. Sirven J. I., Drazkowski J. F., Zimmerman R. S., Bortz J. J., Shulman D. L., Macleish M., Complementary/alternative medicine for epilepsy in Arizona, 10.1212/01.wnl.0000073541.08356.47
  174. Stables, Epilepsy Res, 22, 235 (1995)
  175. Steinman Michael A., Bero Lisa A., Chren Mary-Margaret, Landefeld C. Seth, Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents, 10.7326/0003-4819-145-4-200608150-00008
  176. Sternbach, 5 (1980)
  177. Suzuki, Med Prog, 82, 470 (1972)
  178. Svensmark, Epilepsia, 4, 199 (1963)
  179. SVENSMARK OLE, Diphenylhydantoin And Phenobarbital : Serum Levels in Children, 10.1001/archpedi.1964.02090010084011
  180. Swinyard, Epilepsia, 27, 27 (1986)
  181. Tartara, Epilepsia, 27, 717 (1986)
  182. Tassinari C. A., Michelucci R., Ambrosetto G., Salvi F., Double-blind Study of Vigabatrin in the Treatment of Drug-Resistant Epilepsy, 10.1001/archneur.1987.00520210009010
  183. Tassinari, Epilepsia, 37, 763 (1996)
  184. , Gabapentin as add-on therapy in refractory partial epilepsy: A double-blind, placebo-controlled, parallel-group study, 10.1212/wnl.43.11.2292
  185. Third and Fourth Commissions on Antiepileptic Drugs, International League Against Epilepsy, Epilepsia, 6, 117 (1985)
  186. Thomas, NY Times (1998)
  187. TROUPIN A., OJEMANN L. M., HALPERN L., DODRILL C., WILKUS R., FRIEL P., FEIGL P., Carbamazepine--A double-blind comparison with phenytoin, 10.1212/wnl.27.6.511
  188. UK Gabapentin Study Group, Lancet, 335, 1114 (1990)
  189. Uthman, Arch Neurol, 55, 56 (1998)
  190. Vossen, Dtsch Med Wochenschr, 83, 1227 (1958)
  191. Wang, Lancet Neurol, 5, 46 (2006)
  192. Wheless, J Child Neurol, 19, 135 (2004)
  193. Whitehead, Epilepsy Behav, 3, 405 (2002)
  194. World Health Organization, Atlas: epilepsy care in the world (2005)
  195. Worms, J Pharmacol Exp Ther, 220, 660 (1982)
  196. ZIMMERMAN FREDERIC T., USE OF METHYLPHENYLSUCCINIMIDE IN TREATMENT OF PETIT MAL EPILEPSY, 10.1001/archneurpsyc.1951.02320080040003
  197. ZIMMERMAN FREDERIC T., NEW DRUGS IN THE TREATMENT OF PETIT MAL EPILEPSY, 10.1176/ajp.109.10.767
  198. ZIMMERMAN FREDERIC T., MILONTIN® AND OTHER NEW DRUGS* : IN THE TREATMENT OF PETIT MAL EPILEPSY, 10.1097/00007611-195410000-00004
  199. Zimmerman F. T., Burgemeister B. B., A new drug for petit mal epilepsy, 10.1212/wnl.8.10.769
  200. Bialer, Epilepsy Res, 83, 1 (2009)
  201. Brodie, Epilepsy Behav, 3, 140 (2002)
  202. Shah, Antiepileptic Drugs (2002)
  203. Friedlander, Electrocencephalogr Clin Europhysiol, 3, 311 (1951)
  204. Klein, J Pediar, 37, 733 (1950)
  205. Rowan A. J., Meijer J. W. A., de Beer-Pawlikowski N., van der Geest P., Meinardi H., Valproate-Ethosuximide Combination Therapy for Refractory Absence Seizures, 10.1001/archneur.1983.04050120047006
  206. Sorel, Acta Neurol Psychiatr Belg, 58, 130 (1958)
  207. Turner, Epilepsy: a study of the idiopathic disease (1907)
  208. Wechsler, J Am Med Assoc, 113, 2198 (1940)
  209. Yen, Epilepsia, 41, 1162 (2000)